Recurrent Human Papillomavirus Type 16 Associated Cancer Clinical Trial
Official title:
A Feasibility Trial to Assess Intratumoral Injection of TA-CIN With Anti-PD-1 Therapy for Recurrent HPV16-associated Cancers
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent HPV16-associated cancers undergoing treatment with anti-PD-1 therapy.
n/a